Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

The recent development of immune checkpoint inhibitors (ICIs) has led to promising
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …

Immune checkpoint inhibitors have transformed the prognosis and treatment paradigm of
many cancer types, through the potential for durable responses. However, the majority of …

In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors …

Abstract Background PD-L1 immunohistochemistry (IHC) testing is usually carried out on
tissue blocks from core needle biopsy or surgical resections. In this study, we assessed the …

Background Several biomarkers predict the efficacy of immunotherapy, which is essential for
selecting patients who would potentially benefit. Discordant status of these biomarkers …

Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel
development in anticancer therapy and has been applied to clinical medicine. However …

Simple Summary The lung cancer treatment paradigm has been completely changed by
immunotherapy; however, less than half of the treated patients obtain a response, and an …

Introduction Molecules targeting programmed cell death 1 or its ligand programmed death
ligand 1 (PD-L1) revolutionized the treatment of patients with NSCLC. The only approved …

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-
L1) checkpoint inhibitors have been approved by various regulatory agencies for the …